We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




DNA Test for Bladder Cancer Recurrence

By HospiMedica staff writers
Posted on 13 Aug 2001
A new test for bladder cancer recurrence is based on the detection of genetic changes in bladder cells using fluorescence DNA probe technology. More...
The test has been cleared by the U.S. Food and Drug Administration (FDA) for monitoring recurrence of bladder cancer, and is the first genomic DNA test to be cleared for this purpose.

The test, from Vysis, Inc. (Downer's Grove, IL), is designed to detect aneuploidy for chromosomes 3, 7, 17, and loss of the 9p21 locus via fluorescence in situ hybridization (FISH) in urine specimens from subjects with transitional cell carcinoma. Results from the test, called the UroVysion Kit, are intended for use as a noninvasive method for monitoring tumor recurrence in conjunction with cystoscopy in patients previously diagnosed with bladder cancer.

"We expect this ability to directly visualize genomic abnormalities in cells found in the patient's urine to represent a significant step in helping to improve the management of bladder cancer patients,” said John Bishop, president and CEO of Vysis.





Related Links:
Vysis

Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Patient Preoperative Skin Preparation
BD ChloraPrep
Vessel Sealing Instrument
ERGOseal
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.